Edwards Lifesciences Corporation (NYSE:EW) reported actual EPS of 0.68 in the last Quarter


Edwards Lifesciences Corporation (NYSE:EW) has a 1 Year Target Estimate of $122.1. The stock traded with the volume of 2.77 Million in the last trading session. Edwards Lifesciences Corporation opened at $84.56 and closed by showing a decrease of -0.47%. The Bid price in the last session was $83.50 x 100 and the Ask price was $84.00 x 800. (The ask price is what sellers are willing to take for it. If you are selling a stock, you are going to get the bid price, if you are buying a stock you are going to get the ask price. The difference (or spread) goes to the broker/specialist that handles the transaction).

Edwards Lifesciences Corporation has the Market Capitalization of 17.94 Billion. The Stock has its 52-week High of $121.75 and 52-Week Low of $72.2 and it touched its 52-week high on Oct 10, 2016 and 52-Week Low on Jan 20, 2016.

Edwards Lifesciences Corporation reported its last Earnings on Oct 25 AMC where the company reported Actual EPS of $0.68/Share whereas, the Analyst Estimated EPS was $0.68/share. The difference between Actual EPS and Estimated EPS was $0/share. This represented an Earnings Surprise of 0%. The company will report its next earnings on Jan 31 – Feb 6 (Est.).

20 number of analysts also provided their insight on Edwards Lifesciences Corporation, where the Average Price Target for the stock is $122.1. They also projected Low Price Target as $88 while High Price Target is set at $140.

A number of analysts rated the stock as well: 8 analysts believe that the stock is a STRONG BUY while 10 reported it as Buy.4 analysts assigned a HOLD rating, 0 said it’s UNDERPERFORM and 1 say that this stock is a SELL.

Edwards Lifesciences Corporation annual Divided is 0 while it’s Dividend Yield is 0%. The stock has its Price to Earnings (P/E) ratio of 33.18 and Forward Price to Earnings ratio of 24.62. The company has its Price to Sales (P/S) ratio of 6.26 where Price to Book (P/B) ratio of 6.64, Price to Cash Per share (P/C) of 14.95 and Price to Free Cash Flow (P/FCF) has a value of 43.58.

The company has its Return on Assets (ROA) of 13.5 Percent. Return on Equity (ROE) stands at 22.1% and Return on Investment (ROI) displays a value of 15.9%.

The stock is currently trading at Distance from 20-Day simple moving Average of -6.23% whereas, Distance from 50-Day Simple moving average is -20.48 Percent and Distance from 200-Day Simple Moving Average of -18.78 percent.

A look at performance overview of Edwards Lifesciences Corporation depicts that Performance (Week) is -5.94 percent while Performance Month is -12.75%. Quarterly performance shows a value of -27.25% and Half Year Performance value stands at -15.97%. Yearly performance of the stock has the value of 2.94 percent. Edwards Lifesciences Corporation has its YTD performance of 6.23 Percent. (YTD performance is the most important factor to consider; if YTD is negative, the stock is declining; if the YTD Performance value is Positive the stock is surging).

Insider Trades:

Many Insiders have done trades inside the company. The latest trade was made on 28 Aug 2016 where Chief Operating Officer Hoffman (Marc A) did a transaction type “Sell” in which 10000 shares were traded at a price of $13.92. Another insider trade includes Director Lewis (Thomas A Jr) who also initiated a transaction in which 25000 shares were traded on 16 Aug 2016 as “Sell”. On 14 Aug 2016 Chief Investment Officer Springer (Robert C) traded 32998 shares as “Sell” at $13.81. Director Russell (Keith P) Sell 10000 shares on 13 Jun 2016 at the price of $11.54.

Upgrades/Downgrades Report:

The latest Upgrades/Downgrades was done by Research firm Northland Capital on 8-Nov-16 who Upgrade the stock from Market Perform to Outperform. Other firms have also Upgraded/Downgraded the stock. On 27-Jul-16, BofA/Merrill took an action “Upgrade” from Neutral to Buy. On 9-Jun-16, the stock was Initiated to Neutral by Guggenheim.